[논문]RNA 플랫폼 백신 제조공정 고찰 연구

노형민; 오경석

doi:10.15207/jkcs.2021.12.8.179

RNA 플랫폼 백신 제조공정 고찰 연구
Brief Review on the Processes for RNA-Platform Vaccine Production 원문보기

한국융합학회논문지 = Journal of the Korea Convergence Society, v.12 no.8, 2021년, pp.179 - 186

노형민 (인하공업전문대학 화공환경과) , 오경석 (인하공업전문대학 화공환경과)

초록
AI-Helper

국내 승인된 코로나-19 백신 중, mRNA 플랫폼 기반 백신의 제조공정을 중심으로 살펴보았다. 제조공정은 크게 DNA 주형 제조공정, mRNA 전사공정, 나노에멀젼화 공정, 제형화, 그리고 완제공정으로 이루어져 있다. 이 공정들은 여러 제약사 및 위탁생산회사와 협업으로 진행되고 있다. 이 중 핵심공정인 나노에멀젼화 공정은 mRNA 보호역할을 위해 지질 성분들이 필요하며, 혼합공정에는 microfluidic device를 활용하는 것으로 알려져 있다. 나노에멀젼화 공정 기술은 향후 다양한 의약품 개발에 자극제 역할을 할 것으로 기대된다.

Abstract ▼ AI-Helper

Among the Covid-19 vaccine platforms, mRNA-platform vaccines are summarized qualitatively in this paper. Manufacturing mRNA vaccines consist of serial processes; the preparation process of DNA template, the transcription of mRNA, nanoemulsion process, and the fill and finish unit combined with formulation stages. It is noticeable that major players are collaborated for producing mRNA vaccines. In particular, the nanoemulsion process is recognized to the key process requiring formulated lipid materials to protect modified mRNA until they arrive in intracellular cytosol. It is known that the nanoemulsion process adapts well-designed microfluidic devices. We expect that the nanoemulsion process will stimulate pharmaceutical industries to develop diverse applications.

주제어

표/그림 (7)

표 Table 1. Prices of COVID-19 vaccines [5,6]
표 Table 2. Exemplary platforms of COVID-19 vaccines adapted from WHO data [8]
그림 Fig. 1. Conceptual diagram of bioprocess comparison between viral vector vaccine and mRNA vaccine.
표 Table 3. Comparison of vaccines in current injected in USA and European Union [6,9]
표 Table 4. Enlisted locations of Pfizer, BioNTecch and Moderna and their partners [17-19]
표 Table 5. Lipid ingredients for nanoemulsion of mRNA vaccines [20,21]
표 Table 6. Brief comparison between conventional vaccine and new mRNA vaccine [32]

참고문헌 (32)

J. Cohen. (2021). Unveiling 'Warp Speed', the White House's America-first Push for a Coronavirus Vaccine. Science. doi:10.1126/science.abc7056
M. Bird. (2021-05-06). A Global Operation Warp Speed is Needed to Unlock World-Wide Vaccine Production. Wall Street Journal. https://www.wsj.com/articles/a-global-operation-warp-speed-is-needed-to-unlock-world-wide-vaccine-production-11620285441 (accessed May 24, 2021)
C. Calisher et al. (2020). Statement in Support of the Scientists, Public Health Professionals, and Medical Professionals of China Combatting COVID-19. The Lancet, 395(10226), E42-E43.
K. Oh. (2018). A Study on the Publication of Open Access Artcles. Journal of the Korean Convergence Society, 11(5), 145-151. DOI: 10.15207/JKCS.2020.11.5.145

원문보기 상세보기
J. Gale & L. Beyer. (2021). What's the Best Covid Vaccine? Why It's not So Simple. Bloomberg. https://www.bloomberg.com/news/articles/2021-03-10/what-s-the-best-covid-vaccine-why-it-s-not-so-simple-quicktake
M. Terry. (2021). Updated Comparing COVID-19 Vaccines: Timelines, Types and Prices. Biospace. https://www.biospace.com/article/comparing-covid-19-vaccines-pfizer-biontech-moderna-astrazeneca-oxford-j-and-j-russia-s-sputnik-v/
F. Amant & F. Krammer. (2020). SARS-Cov-2 Vaccines: Status Report. Immunity, 52(4), 583-589. DOI:https://doi.org/10.1016/j.immuni.2020.03.007

상세보기
World Health Organization. (2020). COVID-19 Vaccines. WHO Guidance Document. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines (accessed May 24, 2021)
European Medicines Agency. (2020). COVID-19 Vaccines. EPA Human Regulatory. https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/covid-19-vaccines
European Medicines Agency. (2021). Assessment Report COVID-19 Vaccine AstraZeneca. EMA Human Regulatory. https://www.ema.europa.eu/en/documents/assessment-report/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-public-assessment-report_en.pdf
European Medicines Agency. (2020). Assessment Report COVID-19 Vaccine Janssen.. EMA Human Regulatory. https://www.ema.europa.eu/en/documents/assessment-report/covid-19-vaccine-janssen-epar-public-assessment-report_en.pdf
A. Wolff et al. (1990). Direct Gene Transfer into Mouse Muscle in vivo. Science, 247 (4949 Pt 1), 1465-1468.

상세보기
S. K. Gupta, B. J. Haigh, F. J. Griffin & T. T. Wheeler. (2013). The Mammalian Secreted RNases: Mechanismz of Action in Host Defence. Innate Immunity, 19(1), 86-97.

상세보기
H. J. Park, H. L. Ko, S. Y. Jung, H. B. Jo & J. H. Nam. (2016). The Characteristics of RNA Vaccine; its Strengths and Weaknesses. Journal of Bacteriology and Virology, 46(3), 115-127.

상세보기
K. Kariko, M. Buckstein, H. Ni & D. Weissman, (2005). Suppression of RNA Recognision by Toll-like Receptors: The Impact of Nucleoside Modification and the Evolutionary Origin of RNA. Cell, 23, 165-175.
Springer Nature. (2021). Messengers of Hope. Nat Biotechnol, 39, 1. https://doi.org/10.1038/s41587-020-00807-1

상세보기
C. Scheitz & L. Leidinger. (2021). Exploring the Supply Chain of the Pfizer/BioNTech and Moderna COVID-19 Vaccines. https://blog.jonasneubert.com/2021/01/10/exploring-the-supply-chain-of-the-pfizer-biontech-and-moderna-covid-19-vaccines/
E. Cott, E. deBruyn & J. Coru. (2021). How Pfizer Makes Its Covid-19 Vaccine. New York Times. https://www.nytimes.com/interactive/2021/health/pfizer-coronavirus-vaccine.html
D. Lowe. (2021). RNA Vaccines and Thier Lipids. https://blogs.sciencemag.org/pipeline/archives/2021/01/11/rna-vaccines-and-their-lipids (accessed May 24, 2021)
Centers for Disease Control and Prevention. (2021). Fact Sheet for Recipients and Caregivers Emergency Use Authorization of the Pfizer-BioNTech COVID-19 Vaccine to Prevent COVID-19 in Individuals 12 Years of Age and Older. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/Pfizer-BioNTech.html
Centers for Disease Control and Prevention. (2021). Fact Sheet for Healthcare Providers Administering Vaccine Energency Use Authorization of the Moderna COVID-19 Vaccine to Prevent COVID-19. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/Moderna.html
C. Zeng, C. Zhang, P. G. Walker & Y. Dong. (2020). Formulation and Delivery Technologies for mRNA Vaccines, Current Topics in Microbiology and Immunology. In: Current Topics in Microbiology and Immunology. Berlin, Heidelberg : Springer. DOI: 10.1007/82_2020_217.
L. A. Brito et al. (2014). A Cationic Nanoemulsion for the Delivery of Next-generation RNA Vaccines, Molecular Therapy, 22(12), 2118-2129.

상세보기
M. D. Buschmann, M. J. Carrasco, S. Alishetty, M. Paige, M. G. Alameh & D. Weissman, (2021). Nanomaterial Delivery Systems for mRNA Vaccines, Vaccines, 9, 65.
Y. Singh et al. (2017). Nanoemulsion: Concepts, Development and Applications in Drug Delivery, Journal of Controlled Release, 252, 28-49.

상세보기
H. H. Tayeb & F. Sainsbury. (2018). Nanoemulsions in Drug Delivery: Formation to Medical Application, Nanomedicine, 13(19), 2507-2525. DOI: 10.2217/nnm-2018-0088

상세보기
K. J. Hassett et al. (2021). Optimization of Lipid Nanoparticles for Intramuscular Administration of mRNA Vaccines, Molecular Therapy: Nucleic Acids, 15, 1-11.
Moderna Extends Lipid Supply for Coronavirus Vaccine (2020). CordenPharma. https://www.cordenpharma.com/CordenPharma_and_Moderna_Extend_Lipid_Supply_Agreement_for_Moderna_Vaccine_mRNA-1273_Against_Novel_Coronavirus_SARS-CoV-2
E. Gray. (2020). NASA Supercomputers Power COVID-19 Research. https://www.nasa.gov/feature/esd/2020/nasa-supercomputers-power-covid-19-research
Y. Wang, Z. Zhang. X. Luo, Y. Han & X. Wei. (2021). mRNA Vaccine: A Potential Therapeutic Strategy, Molecular Cancer, 20, 33.

상세보기
M. Wadman. (2020). Will A Small, Long-shot U.S. Company End Up Producing the Best Coronavirus VAccine. Science. https://www.sciencemag.org/news/2020/11/will-small-long-shot-us-company-end-producing-best-coronavirus-vaccine DOI:10.1126/science.abf5474
Advancing Medical Research. (2021). How RNA Technology Could Revolutionize Vaccine Production, Breakthroughs. https://www.breakthroughs.com/advancing-medical-research/how-rna-technology-could-revolutionize-vaccine-production

내보내기 구분	파일저장 인쇄 메일전송
구성항목	기본정보 상세정보 관리번호, 논문명, 저널/프로시딩명, 저자 , 발행년, 권, 호, 시작페이지, 끝페이지, 발행기관 관리번호, 논문명, 대등논문명, 저자 , 저널/프로시딩명, 발행기관, 발행년, 발행언어, 권, 호, 시작페이지, 끝페이지, ISBN, ISSN, 주제분야, 키워드, 초록(한글), 초록(영문), 저자(소속기관)
저장형식	Text(ASCII format) Excel format RefWorks Direct Export RIS format (for Reference Manager, ProCite, EndNote), Scholar's Aids, Mendeley
메일정보	받는사람 (필수) @ 보내는사람 (선택) @ 제목 내용 KISTI 검색결과 이메일 서비스
안내	총 건의 자료가 검색되었습니다. 다운받으실 자료의 인덱스를 입력하세요. (1-10,000) 검색결과의 순서대로 최대 10,000건 까지 다운로드가 가능합니다. 데이타가 많을 경우 속도가 느려질 수 있습니다.(최대 2~3분 소요) 다운로드 파일은 UTF-8 형태로 저장됩니다. 파일의 내용이 제대로 보이지 않을실 때는 웹브라우저 상단의 보기 -> 인코딩 -> 자동선택 여부를 확인하십시오. ~ Text(ASCII format) Excel format

연합인증